17 EyeWorld Asia Pacific | June 2024 Current Accommodating Lenses In Development Creating a true accommodating lens has been a goal for some time in ophthalmology. Several ophthalmologists discussed some of the products currently in development in this space and what makes them unique. Juvene lens by LensGen This lens comes in two parts, said Sumit “Sam” Garg, MD, with a capsule-filling haptic that has an optic in it and also a receptacle for the action part of the lens, which is a fluid lens. Basically, you put that into the capsular bag, and that maintains the capsular volume, Dr. Garg said. Inside that, in a two-part insertion, you place the fluid lens into the eye and then tab it into place. “There are three tabs, and you pop it into place and that’s what supports the lens inside the eye,” he said. The anterior membrane is deformable, and with accommodative effort, it becomes steeper, which gives you the ability to get this range of vision — distance, intermediate, near. The Juvene lens is a silicone and non-diffractive lens. “Some of the limitations we have with the diffractive optics and presbyopia correction go away because it’s non-diffractive, so you’re not as concerned about other pathologies,” he said. “But on the flip side, you get monofocal-like optics with multifocal-like range, and the conversation becomes easier.” Right now, when people talk about lenses, they usually talk about the great range achieved but rarely marry that with the visual quality performance, Dr. Garg said. “They’ll say, ‘I get great quality,’ but don’t talk about the range. This will allow us to do both at the same time, and because of the proposed mechanism of action, I think that’s really intuitive for patients.” Dr. Garg said the Juvene lens takes a bit of patient adaptation. “I think it takes a little while for the eye to get used to, at least what we’ve seen in initial trials,” he said. “It’s not necessarily like you put it in and the next day you have full range. Most people see improvement in near and intermediate over the first month or so, but really after 3 months is when it starts to kick in.” The Juvene lens is not currently in an active trial but the company is ramping up for a Phase 1 FDA trial. All the data published so far has been in exploratory study outside of the U.S., Dr. Garg said, so it’s a different patient population but favorable data. He added that data on the lens has been presented at the ASCRS Annual Meeting and has been published in the Journal of Cataract & Refractive Surgery. “We recently presented 3-year data at ASCRS [and] showed maintenance of magnitude of effect, so whatever accommodation you had at year 1, you saw at year 3,” he said, adding that results were the same in respect to contrast sensitivity. The Juvene lens. Source: Sumit “Sam” Garg, MD, and LensGen by Ellen Stodola, Editorial Co-Director REFRACTIVE SURGERY
RkJQdWJsaXNoZXIy Njk2NTg0